Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. vTv Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was €83.50 Mil. vTv Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €66.42 Mil. Therefore, vTv Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 125.72%.
The historical rank and industry rank for vTv Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
FRA:5VT0'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -70.4 Med: -70.4 Max: 4.78
Current: 4.78
During the past 13 years, vTv Therapeutics's highest Return-on-Tangible-Equity was 4.78%. The lowest was -70.40%. And the median was -70.40%.
FRA:5VT0's Return-on-Tangible-Equity is ranked better than 81.69% of 1196
companies
in the Biotechnology industry
Industry Median: -42.305
vs FRA:5VT0: 4.78
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
vTv Therapeutics Return-on-Tangible-Equity Related Terms
vTv Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs SMNR, CNTB, ENLV: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, vTv Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 125.72% mean?
vTv Therapeutics (FRA:5VT0) has a Return-on-Tangible-Equity of 125.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #219 out of 1196 companies in the Biotechnology industry, placing it in the top 18.3%.
Is vTv Therapeutics' Return-on-Tangible-Equity too high?
vTv Therapeutics' current Return-on-Tangible-Equity is 125.72%. Based on the distribution chart, vTv Therapeutics ranks #219 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Return-on-Tangible-Equity compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #219 out of 1196 companies for Return-on-Tangible-Equity. This places vTv Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Return-on-Tangible-Equity is 125.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Return-on-Tangible-Equity of 125.72%. The stock's GF Value™ is €6,725.03, compared to a current price of €30.20 — trading 99.6% below its estimated fair value. The current Return-on-Tangible-Equity is 125.72%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Return-on-Tangible-Equity is 125.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.20 is trading 99.6% below its estimated GF Value™ of €6,725.03.
Key valuation signals for FRA:5VT0:
Return-on-Tangible-Equity: 125.72%
GF Value™: €6,725.03 vs. price of €30.20 (99.6% below fair value)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
